Not medical advice. LL-37 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
LL-37 is listed in our catalogue under “Immune / Anti-Inflammatory.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
LL-37 human cathelicidin antimicrobial peptide (37 aa, +6 net charge) disrupts bacterial membranes via amphipathic alpha-helical channel formation and NF-κB modulation.
Peer-reviewed literature typically discusses LL-37 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Immune-focused peptides are studied for how they modulate innate responses, viral models, or antimicrobial peptide biology in controlled experiments.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 50-200 μg per day · Once daily subcutaneous injection or topical application · MW ~4493 Da, 37 amino acids with net charge +6 from 16 charged residues. Adopts helix-break-helix conformation in membrane environments. Limitations include susceptibility to proteolytic degradation, dose-dependent cytotoxicity, and high production costs. Vitamin D supplementation upregulates endogenous LL-37 production in vivo.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Resistance is much harder to evolve against membrane-targeting peptides than against receptor- or enzyme-targeting antibiotics, because there is no single protein for the pathogen to mutate. Some bacteria modify their outer membrane charge to reduce electrostatic attraction, but full escape is rare. That is part of why antimicrobial peptides like LL-37 are such a hot research area in the antibiotic-resistance era.
Cathelicidin (CAMP) gene expression is directly regulated by the vitamin D receptor. Calcitriol (the active form of vitamin D) upregulates endogenous LL-37 production, which is one of the mechanisms behind the observed relationship between vitamin D status and susceptibility to respiratory and tuberculosis infections.
Like most amphipathic antimicrobial peptides, LL-37 is selectively toxic to bacterial membranes at low concentrations but loses selectivity at high concentrations, affecting host cell membranes as well. Research protocols need to balance antimicrobial efficacy against host cell tolerability, which is a general limitation of the class.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. LL-37 is susceptible to proteolytic degradation, so use reconstituted material promptly and avoid repeated freeze-thaw cycles.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside LL-37.
Primary literature and registries for LL-37, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: LL-37, Cathelicidin, hCAP-18 Active Fragment, Human Cathelicidin Antimicrobial Peptide, CAMP, Cathelicidin LL-37, Antimicrobial Peptide LL-37